Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.

@article{Li2008DevelopmentON,
  title={Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.},
  author={Bohua Li and Shu Ya Shi and Weizhu Qian and Lei Zhao and Dapeng Zhang and S. -W. Hou and Lei Zheng and Jianxin Dai and Jian Zhao and Hao Wang and Y. -K. Guo},
  journal={Cancer research},
  year={2008},
  volume={68 7},
  pages={2400-8}
}
Despite the effectiveness of the anti-CD20 monoclonal antibody (mAb) Rituximab (C2B8) in the treatment of B-cell lymphoma, its efficacy remains variable and often modest. It seems likely that a combination of multiple mechanisms, such as complement-dependent cytotoxicity (CDC) and apoptotic signaling, underlies the therapeutic success of anti-CD20 mAbs. Unfortunately, all the current anti-CD20 mAbs effective in CDC are relatively inactive in signaling cell death and vice versa. In this study… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Structural basis for recognition of CD20 by therapeutic antibody Rituximab.

The Journal of biological chemistry • 2007
View 3 Excerpts

B cell non-Hodgkin's lymphoma: rituximab safety experience

Arthritis research & therapy • 2005
View 1 Excerpt

Construction and characterization of a humanized anti - human CD 3 monoclonal antibody 12 F 6 with effective immunoregu - lation functions

J Dai
Immunology • 2005

Similar Papers

Loading similar papers…